A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect) - Trial NCT06382987
Access comprehensive clinical trial information for NCT06382987 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
N/A
Jan 22, 2024
Dec 31, 2029
Primary Outcome
Change in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib.,Number of participants who achieved Physician's Global Assessment (PGA) of 0/1 from baseline to follow-up,Number of participants who achieved Absolute Psoriasis Area and Severity Index (aPASI) of ≤2 from baseline to follow-up,Number of participants who achieved Dermatology Life Quality Index (DLQI) of 0 /1 from baseline to follow-up,Participant duration of treatment (time difference between date of treatment initiation to date of discontinuation)
Summary
This is a prospective, observational, real-world study of adult participants in Japan with
 physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06382987
Non-Device Trial